Idacio (Adalimumab)

Adalimumab is a fully human monoclonal antibody that binds specifically to tumor necrosis factor‑alpha (TNF‑α), a cytokine that drives inflammation. By neutralising both soluble and membrane‑bound TNF‑α, the drug blocks the cytokine’s interaction with its receptors on cells, halting downstream inflammatory signaling. This reduces recruitment of immune cells, limits tissue damage, and restores a more balanced immune response.

The dose and frequency of Idacio are set by the prescribing healthcare professional based on the specific indication, patient weight, disease severity, and clinical response. Typical regimens involve subcutaneous injections of 40 mg every other week or weekly, but the exact schedule may vary. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of adalimumab in pregnancy and lactation has not been fully established, and the product’s pregnancy category is listed as unknown. It may be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their physician.

To request Idacio, submit an enquiry on the product page at gnhindia.com, specifying the desired quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including cold‑chain handling for this biologic—and assists with any required import documentation.

Idacio (adalimumab) is a fully human monoclonal antibody, whereas alternatives such as infliximab are chimeric antibodies and etanercept is a fusion protein. All target TNF‑α but differ in molecular structure, dosing frequency, and administration routes. Adalimumab is typically given subcutaneously every two weeks, offering convenient self‑administration, while infliximab requires intravenous infusion. Efficacy across approved indications is comparable, but individual patient factors guide the choice.

Idacio must be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the prefilled syringe in its original packaging, protect it from light, and do not freeze or shake the product. If the temperature rises above the recommended range, the medication should not be used and a replacement should be obtained.

Idacio is supplied as a 40 mg/0.8 mL solution in a prefilled syringe for subcutaneous injection. The injection is typically given into the thigh, abdomen, or upper arm, rotating sites to reduce local irritation. Patients or caregivers are instructed on proper aseptic technique, needle handling, and disposal of used syringes according to local regulations.

The most serious risks include severe infections such as tuberculosis, bacterial sepsis, or opportunistic fungal infections, which can be life‑threatening. There is also an increased risk of certain malignancies, including lymphoma and skin cancers. Autoimmune phenomena such as lupus‑like syndrome, demyelinating disorders, and heart failure exacerbation have been reported. Patients should be monitored closely for signs of infection, new cancers, or neurologic changes.

Idacio is contraindicated in patients with known hypersensitivity to adalimumab or any component of the formulation. It should also be avoided in individuals with active, serious infections (including untreated tuberculosis) and in those receiving live vaccines. Caution is advised for patients with moderate to severe heart failure, demyelinating disease, or a history of malignancy, and the decision to treat should be individualized.